53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” This study discovered that the disposition of LY191704 enantiomers in rats and dogs is both stereoselective and species specific.
124 citations
,
January 1996 in “Dermatology” This article reviews the biochemical properties of 5 alpha-reductase isoforms and highlights the limited dermatological use of inhibitors like finasteride, especially for type 1 isozyme-targeting agents, while suggesting further clinical exploration.
89 citations
,
February 1993 in “Journal of Medicinal Chemistry” This research article focuses on nonsteroidal inhibitors of human type I steroid 5-alpha-reductase but reports no new results.
56 citations
,
December 2002 in “The Journal of Clinical Endocrinology & Metabolism” This study suggests that in human osteoblast-like cells, the 5alpha-reductase type 1 isozyme predominantly catalyzes the conversion of testosterone to DHT, which may play a role in bone homeostasis.